Characteristic Change and Loss of In Vivo Osteogenic Abilities of Human Bone Marrow Stromal Cells During Passage
Characteristic Change and Loss of In Vivo Osteogenic Abilities of Human Bone Marrow Stromal Cells During Passage
复制标题
DOI：
10.1089/ten.tea.2009.0500
复制
发表时间：
2010-02-01
影响因子：
4.1
通讯作者：
Kagami, Hideaki
中科院分区：
文献类型：
--
作者：
Agata, Hideki;Asahina, Izumi;Kagami, Hideaki
尽管人骨髓基质细胞（BMSCs）在移植时具有成骨能力，但对体内成骨能力的相关因素知之甚少。在这里，我们报告所需的条件，为人类骨髓间充质干细胞，以证明他们在体内成骨能力。从健康供体获得BMSCs，并分析其体内成骨能力。移植分析显示，传代次数和成骨诱导的长度显着影响异位骨形成。虽然与1周诱导相比，2周诱导增加了骨形成的成功百分比，但无论成骨诱导的时间长短，BMSCs在第4代后完全丧失了体内成骨能力。尽管他们在体内成骨能力，碱性磷酸酶活性或成骨标志物的基因表达之间的BMSCs在第1代和第3代之间没有显着差异。差异仅在体外矿化能力。碱性成纤维细胞生长因子的应用有助于维持BMSCs在体内的成骨能力;碱性成纤维细胞生长因子改变了细胞的生长和HLA-DR的表达。结果强烈提示，人BMSCs表现出成骨能力需要几个条件，在设计临床骨组织工程方案时应进一步研究和考虑。
Although human bone marrow stromal cells (BMSCs) have the ability to form bone when transplanted, the responsible factors for in vivo osteogenic abilities are poorly understood. Here we report conditions that are required for human BMSCs to demonstrate their in vivo osteogenic abilities. BMSCs were obtained from healthy donors and their in vivo osteogenic abilities were analyzed. Transplantation analyses revealed that the passage number and length of osteogenic induction significantly affected ectopic bone formation. Although 2-week induction increased the percentage of success in bone formation compared with the 1-week induction, BMSCs completely lost their in vivo osteogenic ability after passage 4 regardless of the length of osteogenic induction. Despite their in vivo osteogenic ability, no significant difference was observed in alkaline phosphatase activity or gene expression of osteogenic markers between BMSCs at passages 1 and 3. Differences were only observed in in vitro mineralizing abilities. Application of basic fibroblast growth factor helped to maintain the BMSCs in vivo osteogenic ability; basic fibroblast growth factor altered cell growth and expression of HLA-DR. The results strongly suggest that there are several required conditions for human BMSCs to demonstrate their bone-forming capabilities, which should be further investigated and considered when designing a protocol for clinical bone tissue engineering.